Sequential Intravesical Gemcitabine and Docetaxel for Bacillus Calmette-Guérin-naïve High-risk Nonmuscle-invasive Bladder Cancer: Sequential Intravesical Gemcitabine and Docetaxel for Bacillus Calmette-Guérin-naïve High-risk Nonmuscle-invasive Bladder Cancer

Mehraban Kavoussi; Ali A. Nasrallah; Stephen B. Williams

doi:10.1016/j.eururo.2022.08.024

Sequential Intravesical Gemcitabine and Docetaxel for Bacillus Calmette-Guérin-naïve High-risk Nonmuscle-invasive Bladder Cancer: Sequential Intravesical Gemcitabine and Docetaxel for Bacillus Calmette-Guérin-naïve High-risk Nonmuscle-invasive Bladder Cancer

Mehraban Kavoussi
, Ali A. Nasrallah
, Stephen B. Williams

Surgery

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	659
Number of pages	1
Journal	European Urology
Volume	82
Issue number	6
DOIs	https://doi.org/10.1016/j.eururo.2022.08.024
State	Published - Dec 2022

ASJC Scopus subject areas

Urology

Access to Document

10.1016/j.eururo.2022.08.024

Cite this

Kavoussi, M., Nasrallah, A. A., & Williams, S. B. (2022). Sequential Intravesical Gemcitabine and Docetaxel for Bacillus Calmette-Guérin-naïve High-risk Nonmuscle-invasive Bladder Cancer: Sequential Intravesical Gemcitabine and Docetaxel for Bacillus Calmette-Guérin-naïve High-risk Nonmuscle-invasive Bladder Cancer. European Urology, 82(6), 659. https://doi.org/10.1016/j.eururo.2022.08.024

Sequential Intravesical Gemcitabine and Docetaxel for Bacillus Calmette-Guérin-naïve High-risk Nonmuscle-invasive Bladder Cancer: Sequential Intravesical Gemcitabine and Docetaxel for Bacillus Calmette-Guérin-naïve High-risk Nonmuscle-invasive Bladder Cancer. / Kavoussi, Mehraban; Nasrallah, Ali A.; Williams, Stephen B.
In: European Urology, Vol. 82, No. 6, 12.2022, p. 659.

Research output: Contribution to journal › Comment/debate › peer-review

Kavoussi, M, Nasrallah, AA & Williams, SB 2022, 'Sequential Intravesical Gemcitabine and Docetaxel for Bacillus Calmette-Guérin-naïve High-risk Nonmuscle-invasive Bladder Cancer: Sequential Intravesical Gemcitabine and Docetaxel for Bacillus Calmette-Guérin-naïve High-risk Nonmuscle-invasive Bladder Cancer', European Urology, vol. 82, no. 6, pp. 659. https://doi.org/10.1016/j.eururo.2022.08.024

Kavoussi M, Nasrallah AA, Williams SB. Sequential Intravesical Gemcitabine and Docetaxel for Bacillus Calmette-Guérin-naïve High-risk Nonmuscle-invasive Bladder Cancer: Sequential Intravesical Gemcitabine and Docetaxel for Bacillus Calmette-Guérin-naïve High-risk Nonmuscle-invasive Bladder Cancer. European Urology. 2022 Dec;82(6):659. doi: 10.1016/j.eururo.2022.08.024

Kavoussi, Mehraban ; Nasrallah, Ali A. ; Williams, Stephen B. / Sequential Intravesical Gemcitabine and Docetaxel for Bacillus Calmette-Guérin-naïve High-risk Nonmuscle-invasive Bladder Cancer : Sequential Intravesical Gemcitabine and Docetaxel for Bacillus Calmette-Guérin-naïve High-risk Nonmuscle-invasive Bladder Cancer. In: European Urology. 2022 ; Vol. 82, No. 6. pp. 659.

@article{4224505cf63443f29b013720c75fc98d,

title = "Sequential Intravesical Gemcitabine and Docetaxel for Bacillus Calmette-Gu{\'e}rin-na{\"i}ve High-risk Nonmuscle-invasive Bladder Cancer: Sequential Intravesical Gemcitabine and Docetaxel for Bacillus Calmette-Gu{\'e}rin-na{\"i}ve High-risk Nonmuscle-invasive Bladder Cancer",

author = "Mehraban Kavoussi and Nasrallah, \{Ali A.\} and Williams, \{Stephen B.\}",

note = "Funding Information: Acknowledgments: This study was conducted with the support of a Department of Defense Peer Reviewed Cancer Research Program (PRCRP) Career Development Award (W81XWH1710576) and National Institutes of Health (NIH) Loan Repayment Program.",

year = "2022",

month = dec,

doi = "10.1016/j.eururo.2022.08.024",

language = "English (US)",

volume = "82",

pages = "659",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier B.V.",

number = "6",

}

TY - JOUR

T1 - Sequential Intravesical Gemcitabine and Docetaxel for Bacillus Calmette-Guérin-naïve High-risk Nonmuscle-invasive Bladder Cancer

T2 - Sequential Intravesical Gemcitabine and Docetaxel for Bacillus Calmette-Guérin-naïve High-risk Nonmuscle-invasive Bladder Cancer

AU - Kavoussi, Mehraban

AU - Nasrallah, Ali A.

AU - Williams, Stephen B.

N1 - Funding Information: Acknowledgments: This study was conducted with the support of a Department of Defense Peer Reviewed Cancer Research Program (PRCRP) Career Development Award (W81XWH1710576) and National Institutes of Health (NIH) Loan Repayment Program.

PY - 2022/12

Y1 - 2022/12

UR - https://www.scopus.com/pages/publications/85137743966

UR - https://www.scopus.com/pages/publications/85137743966#tab=citedBy

U2 - 10.1016/j.eururo.2022.08.024

DO - 10.1016/j.eururo.2022.08.024

M3 - Comment/debate

C2 - 36089530

AN - SCOPUS:85137743966

SN - 0302-2838

VL - 82

SP - 659

JO - European Urology

JF - European Urology

IS - 6

ER -

Sequential Intravesical Gemcitabine and Docetaxel for Bacillus Calmette-Guérin-naïve High-risk Nonmuscle-invasive Bladder Cancer: Sequential Intravesical Gemcitabine and Docetaxel for Bacillus Calmette-Guérin-naïve High-risk Nonmuscle-invasive Bladder Cancer

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this